drugset / Trial / NCT02474316

Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients

NCT02474316

Phase 4 Unknown 366 enrolled Ruijin Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA treatment, HBeAg positive CHB patients who achieved HBV DNA\<1000copies/ml but HBeAb negative, will be randomized (1:1) into 2 study arms as follows: Arm A: Peginterferon alfa-2a 180μg /wk plus NA 1 piece qd for 48 weeks Arm B: Entecavir 0.5mg qd for 48 weeks

Timeline

Start
2014-08
Primary completion
2017-12
Completion
2017-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 0.5 mg Oral
Subject Peginterferon alfa-2a Protein / enzyme biologic 180 ug Subcutaneous